News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oxford Gene Technology Ltd. to Share Strategies for Reliable NGS Panel Assays


9/18/2013 9:07:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Oxford, UK – 18 September 2013. Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, will share its expertise in NGS assay design by hosting a live webinar entitled ‘Enhanced bait design strategies that deliver more reliable NGS panel assays’ on 3rd October 2013, at 3:00pm (BST).

Guest speaker, Dr Chris Mattocks, Senior Clinical Research Scientist at the National Genetics Reference Laboratory (Wessex), Salisbury UK, will discuss the advantages of hybridisation enrichment and the importance of optimal bait design to ensure increased uniformity for all target regions.

As the use of NGS moves closer to the clinic, it is of paramount importance that relevant mutations can be detected and called with complete certainty. Only reliable and reproducible methods will inspire enough confidence to allow the transition of NGS assays from useful research tools to clinically dependable tests.

As such, it is becoming increasingly apparent that some NGS enrichment methods do not reliably detect known mutants due to issues with PCR artefacts, excessive off-target enrichment, target region bias, non-uniformity of coverage or even wholesale target region drop-out. This highlights the need for methods with increased uniformity of coverage (when each locus is read at sufficient depth without resorting to increasing the number of reads) and minimal variation between loci, to provide confidence that all loci are covered at dependable levels.

As well as discussing bait design, the webinar will also cover the impact of coverage, non-conformity on sequencing efficiency and cost, and how coverage affects confidence levels in the results.

OGT’s significant expertise in NGS is demonstrated by Genefficiency™ Custom Targeted Sequencing Services, which combine expert bait design with a unique and fully interactive variant analysis report that delivers rapid access to reliable, meaningful results.

To register for the webinar, please visit the sign-up page.

For more information on OGT’s Genefficiency Sequencing Services, contact OGT or visit the website.

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.

T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: contact@ogt.com

W: www.ogt.com ; Twitter: @OxfordGeneTech



About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.

CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES